Literature DB >> 22449929

Lipid nanoparticles for drug targeting to the brain.

Maria Luisa Bondì1, Roberto Di Gesù, Emanuela Fabiola Craparo.   

Abstract

In this chapter, the main production methods of lipid nanostructures such as solid lipid nanoparticles and nanostructured lipid carriers, and their application are described. In particular, we describe the strategies commonly used to obtain lipid nanoparticles to overcome the blood-brain barrier (BBB) for the treatment of several brain diseases. The use of these carriers as targeted drug delivery systems is associated with many advantages that include excellent storage stability, easy production without the use of any organic solvent, the possibility of steam sterilization and lyophilization, and large scale production. They exhibit good stability during long-term storage, consist of physiologically well-tolerated ingredients often already approved for pharmaceutical applications in humans, and are generally recognized as safe. Under optimized conditions, they can be produced to incorporate several drugs and therapeutic proteins. Formulation in solid lipid nanostructures confers improved drug loading and protein stability, targeting, and sustained release of the incorporated molecules. Moreover, their lipophilic features lead them to the central nervous system by an endocytotic mechanism, overcoming the BBB. Many drugs have been incorporated into solid lipid nanosystems and several therapeutic applications may be foreseen, such as targeting with molecules useful for treatment of brain diseases.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449929     DOI: 10.1016/B978-0-12-391860-4.00012-4

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  8 in total

1.  Sophorolipid Butyl Ester Diacetate Does Not Affect Macrophage Polarization but Enhances Astrocytic Glial Fibrillary Acidic Protein Expression at Micromolar Concentrations in Vitro.

Authors:  Alexis M Ziemba; Manoj K Gottipati; Filbert Totsingan; Cheryl M Hanes; Richard A Gross; Michelle R Lennartz; Ryan J Gilbert
Journal:  ACS Chem Neurosci       Date:  2017-02-07       Impact factor: 4.418

Review 2.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 3.  Nano-ART and NeuroAIDS.

Authors:  Malay K Das; Anupam Sarma; Tapash Chakraborty
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

4.  Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability.

Authors:  Shweta Gupta; Rajesh Kesarla; Narendra Chotai; Ambikanandan Misra; Abdelwahab Omri
Journal:  Biomed Res Int       Date:  2017-01-23       Impact factor: 3.411

5.  MiRNA10b-directed nanotherapy effectively targets brain metastases from breast cancer.

Authors:  Byunghee Yoo; Alana Ross; Pamela Pantazopoulos; Zdravka Medarova
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

6.  Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA.

Authors:  Meenakshi Malhotra; Catherine Tomaro-Duchesneau; Shyamali Saha; Imen Kahouli; Satya Prakash
Journal:  Int J Nanomedicine       Date:  2013-05-21

7.  Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings.

Authors:  Dan Li; Ke Yang; Jie-Si Li; Xi-Yu Ke; Yu Duan; Ruo Du; Ping Song; Ke-Fu Yu; Wei Ren; Dan Huang; Xing-Huo Li; Xin Hu; Xuan Zhang; Qiang Zhang
Journal:  Int J Nanomedicine       Date:  2012-12-17

Review 8.  Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier.

Authors:  David Lee; Tamara Minko
Journal:  Pharmaceutics       Date:  2021-11-30       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.